

CORCEPT THERAPEUTICS INC  
Form 8-K/A  
June 21, 2007

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Form 8-K/A**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report: **June 21, 2007**  
(Date of earliest event reported)

**Corcept Therapeutics Incorporated**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**000-50679**  
(Commission File Number)

**77-0487658**  
(I.R.S. Employer Identification No.)

**149 Commonwealth Drive**  
**Menlo Park, CA**  
(Address of principal executive offices)

**94025**  
(zip code)

**(650) 327-3270**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-



**Explanatory statement:** This Form 8-K/A is being filed solely for the purpose of correcting an error in the state of incorporation as reflected on the cover page of the Form 8-K filed on June 21, 2007.

**Item 8.01 Other Events**

On June 21, 2007 Corcept Therapeutics Incorporated issued a press release announcing positive results from its proof of concept study evaluating the ability of CORLUX® to mitigate weight gain associated with Olanzapine.

**Item 9:01 Financial Statements and Exhibits.**

None	(a)	<b>Financial statements:</b>
None	(b)	<b>Pro forma financial information:</b>
None	(c)	<b>Shell company transactions:</b>
99.1	(d)	<b>Exhibits</b>
		<u>Press Release of Corcept Therapeutics Incorporated dated June 21, 2007</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CORCEPT THERAPEUTICS INCORPORATED**

Date: June 21, 2007

By: */s/ Anne LeDoux*  
Anne LeDoux  
Vice President & Controller

-3-

---

**Exhibit Index**

**Exhibit No.**

**Description**

99.1

Press Release of Corcept Therapeutics Incorporated dated June 21, 2007

-4-

---